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g/10.1016/j.urology.2019.09.044Numerous changes have taken place over the past2 decades in relation to the diagnosis and man-agement of patients presenting with renal cell
carcinoma (RCC). Alongside significant continued pro-
jected increases in incidence,1 rates of obesity and tobacco
smoking, established RCC risk factors, have altered2-4 and
there has been a general shift away from radical nephrec-
tomy (RN) to partial nephrectomy (PN),5 and minimally
invasive instead of open procedures.6
Outcomes in patients postnephrectomy for localized
RCC are highly variable, but risk stratification tools have
not evolved during this same period, remain reliant on
clinicopathologic criteria alone and typically explain only
a small proportion of the observed variance in outcomes.7
As clinical practice and tumor biology changes, so too can
the performance of such models and agreement between
observed and predicted outcomes may shift over time.© 2019 The Authors. Published by Elsevier Inc.
This is an open access article under the CC BY license.
(http://creativecommons.org/licenses/by/4.0/)
Indeed, recently reported trials of adjuvant therapy, con-
ducted across North America and Asia, in patients
deemed at high risk of relapse based on tumor stage and
grade, have shown better than expected disease-free
survival rates among placebo-treated patients, when
compared to historical data.8-10
In Europe, the most widely used risk stratification tool is
the Leibovich score, developed in 2003 in patients under-
going RN between 1970 and 2000 at a single high-volume
US centre.11 Its performance in a contemporary, prospec-
tive, multi-institutional European cohort has not been
assessed. We conducted a National Institute for Health
Research funded prospective observational multicenter
cohort study to generate a high-quality biobank with associ-
ated clinical data and follow-up for the evaluation of novel
and emerging prognostic RCC biomarkers.12 Here, utilizing
both this cohort and a distinct historical group of UK
patients, we examine outcomes by the Leibovich score and
reveal alteration in performance of the model over time.METHODS
Patients and Samples
Patients from 11 UK centers with newly diagnosed suspected
RCC, of all stages and histologic types, with no prior treatment,
were eligible. Exclusion criteria were those with known familial
RCC (eg, VHL syndrome), renal cancer acquired following and/
or during renal replacement therapy and those at high risk or
with known HIV, Hepatitis B/C or other blood-borne infectious
disease. Patients undergoing any procedure, including ablation,
radical or PN or biopsy only, were eligible for the overall study,
although only nephrectomized patients were included in the cur-
rent analysis. Baseline clinical, biochemical, and hematological
data were collected, together with follow-up data, all using stan-
dardized case report forms and co-ordinated through the Leeds
Clinical Trials Research Unit. As part of the study, and follow-
ing informed written consent, baseline blood and urine samples
and an Formalin fixed paraffin embedded (FFPE) tumor tissue
block (from patients undergoing nephrectomy) were also col-
lected. The study was approved by the Local Research Ethics
Committee (ethical approval 10/H1306/6). A historical cohort,
composed of patients attending St James’s University Hospital,
Leeds between 1998 and 2006, who had been prospectively
recruited to a local biobanking study using the same eligibility
and exclusion criteria as above were also included as a separate
cohort for comparison.
Pathology
Original pathology reports were requested and tumor type, stage,
size, and lymph node status, as well as presence or absence of
necrosis and sarcomatoid and/or rhabdoid change, extracted. For
clear cell RCC (ccRCC) cases only, the Leibovich score was
also calculated.11 Baseline imaging (CT/MRI) reports were also
reviewed.
Statistical Methods
Metastasis-free survival (MFS) was calculated for patients with
localized disease, defined as the period from date of nephrectomy
to date of distant recurrence. Patients without recurrence were
censored at the date they were last known to be recurrence free
(for patients who died without recurrence this was date of death).UROLOGY 136, 2020Patient characteristics in the contemporary and historic cohorts
were compared using Wilcoxon rank-sum and chi-squared tests.
Where information was available, categorical variables were
compared with data from the original Leibovich cohort.
Performance of the Cox proportional hazard (PH) model on
which the Leibovich score is based was assessed in terms of dis-
crimination, calibration,13 and estimation of explained variation
(EV).14 Cox PH models with Leibovich risk group as predictor
were used to estimate hazard ratios and c-index to assess discrimi-
nation. The Kaplan-Meier method was used to estimate and
visualize MFS to assess calibration. EV was calculated as
described14 using downloadable R scripts15 adapted in house. In
addition to an estimate of EV for the model as a whole, this
method allows for the approximation of the proportion of EV
which can be attributed to individual model elements in both
the univariate (unadjusted EV) and multivariable (adjusted EV)
setting. Unadjusted EV was calculated by including each of the
Leibovich score elements, in turn, into a univariate Cox PH
model with MFS as the response variable. Adjusted EV was cal-
culated as the difference in EV between the Cox PH model
including all elements of the Leibovich score, and the multivari-
able model excluding each of the elements in turn, to give an
estimate for each variable when adjusting for the others.
All statistical tests were 2-sided, all analyses were undertaken
in the R environment for statistical computing.16RESULTS
In total, 706 patients were recruited to the study between July
2011 and June 2014 from 11 UK centers. An RCC was subse-
quently confirmed in 608 (86%) cases with 79% of these being
clear cell, 10% papillary, 8% chromophobe, and 3% unclassified
tumors. Characteristics for all RCC patients are shown in
Supplementary Table S1 with details of patients found not to
have RCC shown in Supplementary Table S2. A flow diagram
of patients is presented in Supplementary Figure S1.
RCC Patients
Leibovich Score Performance. The performance of the Leibo-
vich score was assessed using the same inclusion and exclusion
criteria as the original report,11 with the exception that patients
undergoing PN were included in our analyses to reflect current
practice. Of the 480 ccRCC patients in our contemporary UK
cohort, 384 were eligible and had complete data to allow calcu-
lation of the Leibovich score and MFS. For comparison, and to
examine changes over time in UK cohorts, we examined the
performance of the Leibovich score in a historical cohort of 191
patients undergoing nephrectomy for ccRCC between 1998 and
2006 at a single UK institution (Leeds).
Clinical and demographic characteristics of the contem-
porary ccRCC subcohort and historical cohort are shown in
Table 1, alongside available patient characteristics from the
original Leibovich cohort. Median follow-up in the contem-
porary and historic UK cohorts was 4.4 years (IQR: 3.4, 5.2)
and 10.7 years (IQR: 7.87, 12.71), respectively. Certain ele-
ments of the model, such as tumor necrosis and lymph node
status, have remained constant over time. However, shifts
in the distribution of tumor grade, size, and pT stage are
evident, which start to become apparent when comparing
the Leibovich cohort (1970-2000) with the historic UK
cohort (1998-2006) and persist in the contemporary UK
cohort (2011-2014). These differences would, however, be
expected to be accounted for by the model.163
Table 1. Characteristics of nephrectomized localized ccRCC patients included in analysis
Cohorts
Characteristic
Contemporary UK
2011-2014
n = 384
Historic UK
1998-2006
n = 191
Original Leibovich
1970-2000
n = 1671
Age at procedure Median (range) 63 (29, 92) 64 (29, 86) 65 (24, 89)
Gender Male 252 (66) 110 (58) 1061 (64)
Female 132 (34) 81 (42) 610 (36)
Procedurey,z,x PN 100 (26) 12 (6) 0 (0)
RN 284 (74) 178 (93) 1671 (100)
Missing 0 (0) 1 (1) 0 (0)
Stagez I 227 (59) 93 (49) NA
II 42 (11) 13 (7) NA
III 115 (30) 85 (45) NA
Leibovich Score elements
Tumor size (mm) Median (range) 50 (11, 180) 55 (2, 160) 65 (8, 240)
Tumor sizey,x ≤10 cm 350 (91) 166 (87) 1312 (78)
>10 cm 34 (9) 25 (13) 359 (22)
Gradey,x 1 6 (2) 6 (3) 182 (11)
2 131 (34) 61 (32) 786 (47)
3 200 (52) 94 (49) 600 (36)
4 47 (12) 30 (16) 103 (6)
pT*,y,z,x 1a 126 (33) 45 (24) 384 (23)
1b 102 (27) 48 (25) 440 (26)
2 42 (11) 16 (8) 335 (20)
3 114 (29) 82 (43) 507 (30)
4 0 (0) 0 (0) 5 (1)
pN 0/X 376 (98) 181 (95) 1605 (96)
1 8 (2) 10 (5) 56 (3)
2 0 (0) 0 (0) 10 (1)
Necrosis No 282 (73) 146 (76) 1232 (74)
Yes 102 (27) 45 (24) 439 (26)
Leibovich risk group
Low 150 (39) 60 (31) 689 (41)
Intermediate 163 (42) 86 (45) 608 (36)
High 71 (19) 45 (24) 374 (22)
NA, not available; PN, partial nephrectomy; RN, radical nephrectomy.
* AJCC 2002 TNM staging applied in original Leibovich and historic UK cohorts vs 2010 TNM staging applied to contemporary UK cohort.
yP <.05 Leibovich vs contemporary UK cohort.
zP <.05 contemporary UK vs historic UK cohort.
xP <.05 Leibovich vs historic UK cohort.The c-index of the Cox PH model with risk group as the pre-
dictor in the contemporary UK cohort was 0.77 (SE: 0.04) and
in the historic UK cohort was 0.73 (SE: 0.04), demonstrating
good model discrimination, further evidenced by corresponding
hazard ratios in the intermediate- and high-risk groups; 5.11,
95% CI: (1.77-14.8), and 23.4, 95% CI: (8.30-66.0), respec-
tively, in the contemporary cohort and 4.22, 95% CI: (1.62-
11.0) and 16.1, 95% CI: (6.16-42.2), in the historic cohort
(with low risk the reference).
Figure 1 shows Kaplan-Meier curves for the risk groups in
both UK cohorts and approximate survival curves estimated
from MFS figures reported in the original Leibovich paper, and
comparative 1-, 3-, and 5-year MFS rates are shown in Table 2.
The Kaplan-Meier plots confirm the discriminative ability of the
model to differentiate between risk groups. The agreement of
the survival curves between the historic and original Leibovich
cohorts suggest a degree of calibration, however, the survival
curves for the contemporary cohort in the intermediate- and
high-risk groups are not well aligned with the Leibovich data
curves, indicating some degree of miscalibration. This is also evi-
dent in the observed MFS rates. For example, at year 5, while
MFS rates in the high-risk group in the original and historic164cohorts are similar (31% and 37%, respectively), it is higher in
our contemporary high-risk group (50%).
The percentage of variation explained by the Cox PH model
on which the Leibovich score is based was 28% in the historic
UK cohort and 22% in the contemporary UK cohort (Table 3).
The majority of EV (unadjusted and adjusted) was attributable
to tumor stage in both cohorts, while the contribution of tumor
grade and presence of necrosis to the EV was observed to
decrease with time.DISCUSSION
Our ability to deliver effective patient centered cancer
care depends substantially on our ability to estimate likely
patient outcomes to aid our planning and as part of shared
decision taking. Although clinicopathologic models have
become widely incorporated into clinical pathways to
guide decision making, it should be recognized that the
performance of such models may alter over time and must,
therefore, be periodically re-examined. Here, by example,
we show that the performance of the Leibovich score hasUROLOGY 136, 2020
Figure 1. Metastasis-free survival by Leibovich risk group. Survival curves are shown for patients in the contemporary UK
cohort, a comparative historical UK cohort and the original US cohort as reported by Leibovich et al.11
Table 2. 1-, 3-, and 5-year metastasis-free survival rates by Leibovich risk group
Cohorts
Leibovich Risk Group
Contemporary UK
n = 384
Historic UK
n = 191
Original Leibovich
n = 1671
1-year MFS rate (%) SE
Low 99 § 1 98 § 2 99.5 § 0.3
Intermediate 98 § 1 94 § 3 90.4 § 1.2
High 77 § 5 72 § 7 57.7 § 2.6
3-year MFS rate (%) SE
Low 97 § 1 95 § 3 97.9 § 0.6
Intermediate 91 § 2 79 § 4 79.8 § 1.7
High 62 § 6 45 § 8 37.1 § 2.7
5-year MFS rate (%) SE
Low 97 § 1 93 § 3 97.1 § 0.7
Intermediate 85 § 3 76 § 5 73.8 § 2.0
High 50 § 7 37 § 8 31.2 § 2.7
SE, standard error.
Table 3. Proportion of explained variation by UK cohort. Estimate of explained variation (EV) for the full model and that
which can be attributed to individual model elements in both the univariate (unadjusted EV) and multivariable (adjusted EV)
setting are presented
Historic UK cohort Unadjusted explained variation (%) Adjusted explained variation (%)
pT 16.84 5.35
pN 2.47 0.20
Tumor ≥100 mm 5.91 0.47
Grade 12.53 2.97
Necrosis 14.07 3.75
Full model 27.95
Contemporary UK cohort Unadjusted explained variation (%) Adjusted explained variation (%)
pT 14.86 6.95
pN 3.33 0.13
Tumor ≥100 mm 5.88 0.57
Grade 8.01 1.48
Necrosis 8.53 1.11
Full model 21.75
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altered with time, carrying potential implications for other
prognostic models, developed more than a decade ago,
both in localized RCC,17-19 and other settings.
The discriminative ability of the Leibovich model
appears to have been retained over time, with a similar c-
index in both the current cohort as well as in a historical
UK cohort, which we examined for comparative purposes
and to try to control for factors other than time of recruit-
ment (such as a UK vs US setting). Furthermore, the distri-
bution of patients across low-, intermediate-, and high-risk
groups has remained constant. Although absence of base-
line survival function (or raw data) from the original Leibo-
vich study limits options with regards to assessing model
calibration, our indirect assessment of calibration implies a
decline over time.While MFS rates were remarkably similar
between the original Leibovich cohort and our historical
cohort, patients in our contemporary cohort demonstrated
reduced relapse rates among intermediate- and high-risk
groups. For example, the 5-year MFS among high-risk
patients in the original Leibovich, historic and contempo-
rary cohorts was 31.2%, 37%, and 50%, respectively.
This is important given that the Leibovich score is widely
employed in the clinic to counsel patients, guide intensity of
follow-up and for the design and powering of adjuvant
studies. Ongoing phase III trials (eg, NCT03288532),
examining the efficacy of adjuvant checkpoint inhibitors,
include patients with intermediate-risk disease as defined
by the Leibovich score, although our findings suggest that
the majority (85%) of these patients remain metastasis free
at 5 years, and therefore likely cured, through surgery alone.
Given the associated costs, resource implications and
potential toxicity of immunotherapy, it is imperative that
patient selection is optimized and that the performance of
risk stratification tools in the population in which they are
being applied is understood and accounted for.
The reasons for the improvement in MFS rates and alter-
ation in performance of the model over time are uncertain.
It is likely, however, that changes in practice, such as
advances in imaging, improvements in surgical techniques
and refinement of grading and classification of tumors that
have taken place over the past 2 decades are, at least in
part, responsible. Retrospective vs prospective data collec-
tion, varying geographical location and methodological dif-
ferences may also be considered, although we have tried to
account for this by including a historical UK cohort of
patients and by replicating the original study design as
closely as possible. It is also important to recognize that,
while the elements making up the Leibovich score repre-
sent independent prognostic factors in patients with
resected ccRCC,20 the importance of even such strong
prognostic factors in determining outcome at an individual
patient level is often low.7 Methods to quantify this
(termed explained variance) have long been developed
and recently highlighted,7 although as a concept remains
poorly understood and underutilized. We found that the
Leibovich model accounted for just 28% of the observed
variance in MFS in our historical cohort, declining to 22%
among contemporary patients. Thus, the majority of the166variance in outcomes remains unexplained by the model
and refinement limited to consideration of additional clini-
cal factors alone21 seems unlikely to meaningfully improve
this situation. Differences in molecular tumor biology, for
example, that are likely to be critical in determining indi-
vidual outcomes, remain unaccounted for and poorly
defined. Even small changes in these unknown variables
over time, conceivably in this case due to shifts in rates of
obesity, smoking, and hypertension, are likely to signifi-
cantly impact the performance of a given model.
Only a small number of studies have examined the per-
formance of the Leibovich score since its original descrip-
tion. These include a retrospective study among Asian
patients (n = 355) undergoing nephrectomy between 1990
and 200622 and a second, much larger, retrospective Euro-
pean single institution study of patients undergoing
nephrectomy between 1984 and 2006.23 The discrimina-
tive ability of the Leibovich score was confirmed in both
studies, with 5-year DFS rates of 76.8% and 33.6% for
intermediate- and high-risk groups in the former study,
which are comparable to those originally reported.11,22 A
more contemporary, but again retrospective, study of 386
patients conducted in Norway between 1993 and 2013
reported suboptimal calibration for patients in the interme-
diate- and high-risk groups, with a 5-year relapse-free sur-
vival among high-risk patients of 41.2%, in support of our
current findings.24 More recently still, the performance of
8 different prognostic models, including the Leibovich
score, has been reported among US patients recruited to
the phase III adjuvant ASSURE trial between 2006 and
2010.25 The 5-year MFS rates were 79.6% (95% CI: 76.5-
82.4) and 61.8% (57.2-66.1) among Leibovich-score
defined intermediate- and high-risk patients, respectively,
with a c-index for the model of 0.625 (0.623-0.626).26
While our data demonstrate better maintained discrimina-
tory ability of the Leibovich model, the observed improve-
ment in MFS rates over time are consistent with our
findings in our UK cohort of patients. Furthermore, the fact
that the majority (95%) of patients in ASSURE underwent
a RN suggests that the inclusion of patients undergoing a
PN does not account for these differences.
The strengths of this study include its multicenter pro-
spective design, with comprehensive baseline and follow-
up data collection and the inclusion of a comparative his-
torical cohort of UK patients. As one of the main study
objectives, a translational biobank has been generated, to
support the validation of prognostic and diagnostic RCC
biomarkers. Limitations include the lack of central pathol-
ogy review and a shorter median length of follow-up of
4.4 years in the current cohort, compared to 5.4 years as
originally reported by Leibovich et al.11CONCLUSION
In summary, we provide the most contemporary assess-
ment of the Leibovich score to date and show that out-
comes for patients classified as being at intermediate- or
high risk have altered over time. Our findings carryUROLOGY 136, 2020
implications for this model, and potentially other nomo-
grams applied in this or other settings, to guide clinical
decision-making. Identification of patients destined to
relapse remains suboptimal, highlighting the need for
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spective trial-based validation. J Clin Oncol. 2019;37:2062–2071.EDITORIAL COMMENTOncologists have a great need to estimate treatment outcomes
for their patients in order to counsel them properly, plan follow-
up imaging to detect and treat recurrences, and refer for addi-
tional treatment and clinical trials. In the early surgical experi-
ence with renal cell carcinoma (RCC), tumors were large, often
palpable, and with symptoms of bleeding and pain. Radical
nephrectomy was the only effective treatment. Staging systems
(Robson, TMN, AJCC, IUAC) described the local extent of the
tumor, involvement of regional lymph nodes, and the presence
of distant metastases to generate survival distributions in surgical
series. Over the last 50 years, progress in surgery, pathology, radi-
ology, medical oncology, and molecular biology have dramati-
cally changed the RCC landscape. Nearly 70% of tumors today
are considered small (<4 cm) and detected incidentally. Begin-
ning in the early 2000’s and continuing today, nomograms and
prognostic algorithms were generated by centers with compre-
hensive RCC research programs in both clinically localized and
metastatic disease patients. Models incorporated important prog-
nostic features of kidney cancer pathology (histologic sub types,
necrosis, vascular invasion, sarcomatoid elements) and clinical
features (performance status, systemic symptoms, anemia, LDH,
adjusted calcium, neutrophil counts, serum albumin levels, and
bone metastases) to enhance their predictive value over prior167
staging systems. Concordance indices for these models are gener-
ally between 0.7 and 0.8, far better than a coin flip but not a per-
fect 1.0 by any means. Risk assignments (poor, intermediate, and
good) were made and reflected not only the RCC prognostic fac-
tors but evolving improvements in disease management
approaches including diagnostic imaging (MRI, CT, and PET),
surgical approaches (evolution of partial nephrectomy, cytore-
ductive nephrectomy), and pathologic expertise (cytogenetics,
immunohistochemistry, gene, and protein expression markers).
It is not surprising that the authors report discrepancies in 3-
and 5-year metastasis-free survival when applying a single model,
the Mayo Clinic risk stratification score, to their multicenter con-
temporary (2011-2014) cohort of patients (85%, 50%) compared
to the Mayo Clinic cohort (1970-2006) series (74%, 31%). The
authors are concerned that risk assignment systems derived from
historical patient cohorts may overestimate the likelihood of a
poor outcome when applied to patients managed today with cur-
rent clinical and pathologic tools. For investigators designing
adjuvant clinical trials, this kind of information is critical when
estimating the number of patients (power) required to address the
question at hand. As adjuvant trials unfold, data monitoring com-
mittees must be sure that enough events are occurring in the study
arms for meaningful comparisons to be made when the trial is fully
accrued. The breath-taking expansion in knowledge of the cellu-
lar, metabolic, and molecular elements of RCC and its more than
31 distinct histologic subtypes leaves open the opportunity for
new biomarkers to be added to previously studied prediction tools.
However, simply replacing traditional prognostic factors with
molecular biomarkers without improving predictive accuracy will
not provide an effective advance. In the end, the desire to signifi-
cantly improve the accuracy of these prediction tools may ulti-
mately be limited by the molecular complexity and tumor
heterogeneity characteristic of RCC.
Paul Russo, Professor of Urology, Attending Surgeon,
Weill Cornell School of Medicine, Memorial Sloan Kettering
Cancer Center, New York, NY
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which we examine the performance of the Mayo Clinic risk
stratification score (or Leibovich score)1 in UK patients with
localized clear cell renal cell carcinoma (RCC). Outcomes
by metastasis-free survival among intermediate- or high-risk
patients, according to the model, have improved over time. The
implications of this for the clinic are important and readily
apparent, since the model is widely employed to counsel
patients, guide intensity of follow-up and for the design and
powering of adjuvant trials. Our results mirror those of those
of other recently reported data among US patients.2
The reasons behind this alteration in performance are likely
multifactorial. As highlighted, progress in imaging, surgical tech-
nique and pathologic review that have taken place over the past
several decades must be considered. A further, often overlooked,
explanation may come from the fact that even our best current168prognostic markers (in this case tumor size, stage, grade, and
presence or absence of necrosis) are still relatively poor at deter-
mining outcome at an individual patient level. The Mayo Clinic
risk stratification score, among our contemporary cohort of
patients, accounted for just 22% of the observed variance in
metastasis-free survival. In other words, the majority of the
observed variance remains unexplained by the model alone.
The molecular complexity and heterogeneity that character-
izes RCC, as alluded to by the editor(s), remains unaccounted
for in prognostic nomograms limited to gross pathology alone. If
the goal of delivering truly personalized care to patients is to be
met, robust biomarkers that can add value to and further refine
existing riskstratification tools must be identified. We acknowl-
edge the challenges in achieving this, but assays such as the
16-gene recurrence score,3,4 for example, provide sufficient
promise to suggest these challenges are surmountable.
Successful translation of biomarkers to the clinic has been ham-
pered both by a lack of a clearly defined evaluative infrastructure
as well as limited availability of high quality, clinically annotated,
biobanks of sufficient size to allow meaningful late-stage assess-
ment of biomarker performance, as we have recently highlighted.5
Underpinning the current study, samples of serum, plasma, and
urine were collected by strict standard operating procedures prior
to surgery in all patients, including healthy controls, and in a sub-
set of RCC patients (n = 200) longitudinally for up to 2 years. An
archival tissue block was also collected. This multicenter UK
RCC research tissue bank represents an important resource
for prognostic and diagnostic biomarker validation studies in this
disease and collaborative access is welcomed.
The use of prognostic models to individualize our approach to
patient care remains integral to oncological practice. Model per-
formance is, however, susceptible to alteration over time and peri-
odic re-evaluation is necessary. Advances in -omic technologies
are set to give us much more information to improve our ability
to predict outcome, but at present we have to be very careful not
to overestimate the accuracy and stability of prognostic indices.
Naveen S. Vasudev, Peter J. Selby, Rosamonde E.
Banks, Leeds Institute of Medical Research at St James’s,
St. James’s University Hospital, Leeds, UK
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